{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T19:56:24Z","timestamp":1769802984305,"version":"3.49.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Shandong Key Laboratory of Medicine and Prevention Integration in Rheumatism and Immunity Disease"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s10067-025-07882-2","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T02:35:38Z","timestamp":1765766138000},"page":"1279-1289","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Predictors of adverse pregnancy outcomes in systemic lupus erythematosus: A retrospective cohort study"],"prefix":"10.1007","volume":"45","author":[{"given":"Yintao","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shasha","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2051-8643","authenticated-orcid":false,"given":"Lijun","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"key":"7882_CR1","doi-asserted-by":"publisher","first-page":"ITC81","DOI":"10.7326\/AITC202006020","volume":"172","author":"M Kiriakidou","year":"2020","unstructured":"Kiriakidou M, Ching CL (2020) Systemic lupus erythematosus. Ann Intern Med 172:ITC81\u2013ITC96. https:\/\/doi.org\/10.7326\/AITC202006020","journal-title":"Ann Intern Med"},{"key":"7882_CR2","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1056\/NEJMra1100359","volume":"365","author":"GC Tsokos","year":"2011","unstructured":"Tsokos GC (2011) Systemic lupus erythematosus. N Engl J Med 365:2110\u20132121. https:\/\/doi.org\/10.1056\/NEJMra1100359","journal-title":"N Engl J Med"},{"key":"7882_CR3","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","volume":"377","author":"SV Navarra","year":"2011","unstructured":"Navarra SV, Guzman RM, Gallacher AE et al (2011) Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377:721\u2013731. https:\/\/doi.org\/10.1016\/S0140-6736(10)61354-2","journal-title":"Lancet"},{"key":"7882_CR4","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1002\/art.30613","volume":"63","author":"R Furie","year":"2011","unstructured":"Furie R, Petri M, Zamani O et al (2011) A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 63:3918\u20133930. https:\/\/doi.org\/10.1002\/art.30613","journal-title":"Arthritis Rheum"},{"key":"7882_CR5","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1136\/annrheumdis-2017-211631","volume":"77","author":"F Zhang","year":"2018","unstructured":"Zhang F, Bae SC, Bass D et al (2018) A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea. Ann Rheum Dis 77:355\u2013363. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211631","journal-title":"Ann Rheum Dis"},{"key":"7882_CR6","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/art.42392","volume":"75","author":"KC Kalunian","year":"2023","unstructured":"Kalunian KC, Furie R, Morand EF et al (2023) A randomized, placebo-controlled phase III extension trial of the long-term safety and tolerability of anifrolumab in active systemic lupus erythematosus. Arthritis Rheumatol 75:253\u2013265. https:\/\/doi.org\/10.1002\/art.42392","journal-title":"Arthritis Rheumatol"},{"key":"7882_CR7","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1912196","volume":"382","author":"EF Morand","year":"2020","unstructured":"Morand EF, Furie R, Tanaka Y et al (2020) Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med 382:211\u2013221. https:\/\/doi.org\/10.1056\/NEJMoa1912196","journal-title":"N Engl J Med"},{"key":"7882_CR8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/ard-2023-224762","volume":"83","author":"A Fanouriakis","year":"2024","unstructured":"Fanouriakis A, Kostopoulou M, Andersen J et al (2024) EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis 83:15\u201329. https:\/\/doi.org\/10.1136\/ard-2023-224762","journal-title":"Ann Rheum Dis"},{"key":"7882_CR9","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41584-018-0133-2","volume":"15","author":"M Gatto","year":"2019","unstructured":"Gatto M, Zen M, Iaccarino L, Doria A (2019) New therapeutic strategies in systemic lupus erythematosus management. Nat Rev Rheumatol 15:30\u201348. https:\/\/doi.org\/10.1038\/s41584-018-0133-2","journal-title":"Nat Rev Rheumatol"},{"key":"7882_CR10","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/s41584-022-00807-2","volume":"18","author":"S Onuora","year":"2022","unstructured":"Onuora S (2022) Pregnancy outcomes in SLE have not improved. Nat Rev Rheumatol 18:431. https:\/\/doi.org\/10.1038\/s41584-022-00807-2","journal-title":"Nat Rev Rheumatol"},{"key":"7882_CR11","doi-asserted-by":"publisher","first-page":"153","DOI":"10.7326\/M14-2235","volume":"163","author":"JP Buyon","year":"2015","unstructured":"Buyon JP, Kim MY, Guerra MM et al (2015) Predictors of pregnancy outcomes in patients with lupus: a cohort study. Ann Intern Med 163:153\u2013163. https:\/\/doi.org\/10.7326\/M14-2235","journal-title":"Ann Intern Med"},{"key":"7882_CR12","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2174\/1874312900802010089","volume":"2","author":"S Yan Yuen","year":"2008","unstructured":"Yan Yuen S, Krizova A, Ouimet JM, Pope JE (2008) Pregnancy outcome in systemic lupus erythematosus (SLE) is improving: results from a case control study and literature review. Open Rheumatol J 2:89\u201398. https:\/\/doi.org\/10.2174\/1874312900802010089","journal-title":"Open Rheumatol J"},{"key":"7882_CR13","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1177\/0961203316686704","volume":"26","author":"S Wei","year":"2017","unstructured":"Wei S, Lai K, Yang Z, Zeng K (2017) Systemic lupus erythematosus and risk of preterm birth: a systematic review and meta-analysis of observational studies. Lupus 26:563\u2013571. https:\/\/doi.org\/10.1177\/0961203316686704","journal-title":"Lupus"},{"key":"7882_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2024.03.010","author":"CNH Abheiden","year":"2024","unstructured":"Abheiden CNH, Blomjous BS, Slaager C et al (2024) Systemic lupus erythematosus is associated with an increased frequency of spontaneous preterm births: systematic review and meta-analysis. Am J Obstet Gynecol. https:\/\/doi.org\/10.1016\/j.ajog.2024.03.010","journal-title":"Am J Obstet Gynecol"},{"key":"7882_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002752","author":"B Mehta","year":"2023","unstructured":"Mehta B, Jannat-Khah D, Glaser KK et al (2023) Fetal and maternal morbidity in pregnant patients with lupus: a 10-year US nationwide analysis. RMD Open. https:\/\/doi.org\/10.1136\/rmdopen-2022-002752","journal-title":"RMD Open"},{"key":"7882_CR16","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.berh.2017.09.011","volume":"31","author":"R Fischer-Betz","year":"2017","unstructured":"Fischer-Betz R, Specker C (2017) Pregnancy in systemic lupus erythematosus and antiphospholipid syndrome. Best Pract Res Clin Rheumatol 31:397\u2013414. https:\/\/doi.org\/10.1016\/j.berh.2017.09.011","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"127","key":"7882_CR17","doi-asserted-by":"publisher","first-page":"e121","DOI":"10.1016\/j.ajog.2008.03.012","volume":"199","author":"ME Clowse","year":"2008","unstructured":"Clowse ME, Jamison M, Myers E, James AH (2008) A national study of the complications of lupus in pregnancy. Am J Obstet Gynecol 199(127):e121-126. https:\/\/doi.org\/10.1016\/j.ajog.2008.03.012","journal-title":"Am J Obstet Gynecol"},{"key":"7882_CR18","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2024.2324005","author":"J Huang","year":"2024","unstructured":"Huang J, Zhu Q, Wang B et al (2024) Antiphospholipid antibodies and the risk of adverse pregnancy outcomes in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Expert Rev Clin Immunol. https:\/\/doi.org\/10.1080\/1744666X.2024.2324005","journal-title":"Expert Rev Clin Immunol"},{"key":"7882_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2015-000131","volume":"3","author":"CM Yelnik","year":"2016","unstructured":"Yelnik CM, Laskin CA, Porter TF et al (2016) Lupus anticoagulant is the main predictor of adverse pregnancy outcomes in aPL-positive patients: validation of PROMISSE study results. Lupus Sci Med 3:e000131. https:\/\/doi.org\/10.1136\/lupus-2015-000131","journal-title":"Lupus Sci Med"},{"key":"7882_CR20","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1002\/art.34402","volume":"64","author":"MD Lockshin","year":"2012","unstructured":"Lockshin MD, Kim M, Laskin CA et al (2012) Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. Arthritis Rheum 64:2311\u20132318. https:\/\/doi.org\/10.1002\/art.34402","journal-title":"Arthritis Rheum"},{"key":"7882_CR21","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1177\/09612033211004716","volume":"30","author":"K Bremme","year":"2021","unstructured":"Bremme K, Honkanen S, Gunnarsson I, Chaireti R (2021) The presence of lupus nephritis additionally increases the risk of preeclampsia among pregnant women with systemic lupus erythematosus. Lupus 30:1031\u20131038. https:\/\/doi.org\/10.1177\/09612033211004716","journal-title":"Lupus"},{"key":"7882_CR22","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.jaut.2016.07.010","volume":"74","author":"G Moroni","year":"2016","unstructured":"Moroni G, Doria A, Giglio E et al (2016) Fetal outcome and recommendations of pregnancies in lupus nephritis in the 21st century. A prospective multicenter study. J Autoimmun 74:6\u201312. https:\/\/doi.org\/10.1016\/j.jaut.2016.07.010","journal-title":"J Autoimmun"},{"key":"7882_CR23","doi-asserted-by":"publisher","first-page":"B41","DOI":"10.1016\/j.ajog.2022.09.001","volume":"228","author":"R Silver","year":"2023","unstructured":"Silver R, Craigo S et al (2023) Society for maternal-fetal medicine consult series #64: systemic lupus erythematosus in pregnancy. Am J Obstet Gynecol 228:B41\u2013B60. https:\/\/doi.org\/10.1016\/j.ajog.2022.09.001","journal-title":"Am J Obstet Gynecol"},{"key":"7882_CR24","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1002\/1529-0131(199709)40:9<1725::AID-ART29>3.0.CO;2-Y","volume":"40","author":"MC Hochberg","year":"1997","unstructured":"Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725. https:\/\/doi.org\/10.1002\/1529-0131(199709)40:9<1725::AID-ART29>3.0.CO;2-Y","journal-title":"Arthritis Rheum"},{"key":"7882_CR25","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1002\/art.40930","volume":"71","author":"M Aringer","year":"2019","unstructured":"Aringer M, Costenbader K, Daikh D et al (2019) 2019 European league against rheumatism\/American college of rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol 71:1400\u20131412. https:\/\/doi.org\/10.1002\/art.40930","journal-title":"Arthritis Rheumatol"},{"key":"7882_CR26","first-page":"288","volume":"29","author":"DD Gladman","year":"2002","unstructured":"Gladman DD, Ibanez D, Urowitz MB (2002) Systemic lupus erythematosus disease activity index 2000. J Rheumatol 29:288\u2013291","journal-title":"J Rheumatol"},{"key":"7882_CR27","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1161\/CIRCRESAHA.118.313276","volume":"124","author":"S Rana","year":"2019","unstructured":"Rana S, Lemoine E, Granger JP, Karumanchi SA (2019) Preeclampsia: pathophysiology, challenges, and perspectives. Circ Res 124:1094\u20131112. https:\/\/doi.org\/10.1161\/CIRCRESAHA.118.313276","journal-title":"Circ Res"},{"key":"7882_CR28","first-page":"163","volume":"17","author":"E Bili","year":"2013","unstructured":"Bili E, Tsolakidis D, Stangou S, Tarlatzis B (2013) Pregnancy management and outcome in women with chronic kidney disease. Hippokratia 17:163\u2013168","journal-title":"Hippokratia"},{"key":"7882_CR29","doi-asserted-by":"publisher","first-page":"e667","DOI":"10.1016\/S2665-9913(24)00160-7","volume":"6","author":"M Wind","year":"2024","unstructured":"Wind M, Fierro JJ, Bloemenkamp KWM et al (2024) Pregnancy outcome predictors in systemic lupus erythematosus: a systematic review and meta-analysis. Lancet Rheumatol 6:e667\u2013e683. https:\/\/doi.org\/10.1016\/S2665-9913(24)00160-7","journal-title":"Lancet Rheumatol"},{"key":"7882_CR30","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1093\/ckj\/sfac060","volume":"15","author":"O Cabarcas-Barbosa","year":"2022","unstructured":"Cabarcas-Barbosa O, Capalbo O, Ferrero-Fernandez A, Musso CG (2022) Kidney-placenta crosstalk in health and disease. Clin Kidney J 15:1284\u20131289. https:\/\/doi.org\/10.1093\/ckj\/sfac060","journal-title":"Clin Kidney J"},{"key":"7882_CR31","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1177\/09612033231176268","volume":"32","author":"H Shimada","year":"2023","unstructured":"Shimada H, Wakiya R, Kameda T et al (2023) Immunological disease activity parameters at conception are risk factors for preterm birth and low birth weight in patients with systemic lupus erythematosus. Lupus 32:833\u2013841. https:\/\/doi.org\/10.1177\/09612033231176268","journal-title":"Lupus"},{"key":"7882_CR32","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s13075-021-02522-x","volume":"23","author":"Y Hiramatsu","year":"2021","unstructured":"Hiramatsu Y, Isoda K, Kotani T et al (2021) Pre-pregnancy serum complement C3 level is a predictor of preterm birth for pregnancies with systemic lupus erythematosus. Arthritis Res Ther 23:140. https:\/\/doi.org\/10.1186\/s13075-021-02522-x","journal-title":"Arthritis Res Ther"},{"key":"7882_CR33","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.4049\/jimmunol.151.3.1562","volume":"151","author":"F Tedesco","year":"1993","unstructured":"Tedesco F, Narchi G, Radillo O et al (1993) Susceptibility of human trophoblast to killing by human complement and the role of the complement regulatory proteins. J Immunol 151:1562\u20131570","journal-title":"J Immunol"},{"key":"7882_CR34","doi-asserted-by":"publisher","first-page":"707","DOI":"10.3899\/jrheum.200802","volume":"48","author":"JW Kim","year":"2021","unstructured":"Kim JW, Jung JY, Kim HA et al (2021) Lupus low disease activity state achievement is important for reducing adverse outcomes in pregnant patients with systemic lupus erythematosus. J Rheumatol 48:707\u2013716. https:\/\/doi.org\/10.3899\/jrheum.200802","journal-title":"J Rheumatol"},{"key":"7882_CR35","doi-asserted-by":"publisher","first-page":"300060523122534","DOI":"10.1177\/03000605231225349","volume":"52","author":"N Al-Husban","year":"2024","unstructured":"Al-Husban N, Abu-Hassan DW, Saleem RAA et al (2024) Therapeutic changes of systemic lupus erythematosus (SLE) patients in pregnancy and feto-maternal outcomes: a retrospective cohort study. J Int Med Res 52:3000605231225349. https:\/\/doi.org\/10.1177\/03000605231225349","journal-title":"J Int Med Res"},{"key":"7882_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.941586","volume":"13","author":"AS Castellanos Gutierrez","year":"2022","unstructured":"Castellanos Gutierrez AS, Figueras F, Morales-Prieto DM et al (2022) Placental damage in pregnancies with systemic lupus erythematosus: a narrative review. Front Immunol 13:941586. https:\/\/doi.org\/10.3389\/fimmu.2022.941586","journal-title":"Front Immunol"},{"key":"7882_CR37","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1002\/art.41191","volume":"72","author":"LR Sammaritano","year":"2020","unstructured":"Sammaritano LR, Bermas BL, Chakravarty EE et al (2020) 2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. Arthritis Rheum 72:529\u2013556. https:\/\/doi.org\/10.1002\/art.41191","journal-title":"Arthritis Rheum"},{"key":"7882_CR38","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1136\/annrheumdis-2016-209770","volume":"76","author":"L Andreoli","year":"2017","unstructured":"Andreoli L, Bertsias GK, Agmon-Levin N et al (2017) EULAR recommendations for women\u2019s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and\/or antiphospholipid syndrome. Ann Rheum Dis 76:476\u2013485. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209770","journal-title":"Ann Rheum Dis"},{"key":"7882_CR39","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1093\/rheumatology\/keae454","volume":"63","author":"R Dhital","year":"2024","unstructured":"Dhital R, Jacobs M, Smith CJF, Parast MM (2024) Placental lesions in systemic lupus erythematosus pregnancies associated with small for gestational age infants. Rheumatology (Oxford) 63:3006\u20133014. https:\/\/doi.org\/10.1093\/rheumatology\/keae454","journal-title":"Rheumatology (Oxford)"},{"key":"7882_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijms.2021.116550","author":"C Niu","year":"2021","unstructured":"Niu C, Du Y, Kaltashov IA (2021) Towards better understanding of the heparin role in NETosis: feasibility of using native mass spectrometry to monitor interactions of neutrophil elastase with heparin oligomers. Int J Mass Spectrom. https:\/\/doi.org\/10.1016\/j.ijms.2021.116550","journal-title":"Int J Mass Spectrom"},{"key":"7882_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102969","volume":"59","author":"B Buijsers","year":"2020","unstructured":"Buijsers B, Yanginlar C, Maciej-Hulme ML, de Mast Q, van der Vlag J (2020) Beneficial non-anticoagulant mechanisms underlying heparin treatment of COVID-19 patients. EBioMedicine 59:102969. https:\/\/doi.org\/10.1016\/j.ebiom.2020.102969","journal-title":"EBioMedicine"},{"key":"7882_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-8-71","volume":"8","author":"JP Souza","year":"2010","unstructured":"Souza JP, Gulmezoglu A, Lumbiganon P et al (2010) Caesarean section without medical indications is associated with an increased risk of adverse short-term maternal outcomes: the 2004\u20132008 WHO global survey on maternal and perinatal health. BMC Med 8:71. https:\/\/doi.org\/10.1186\/1741-7015-8-71","journal-title":"BMC Med"},{"key":"7882_CR43","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.2215\/CJN.00240110","volume":"5","author":"A Smyth","year":"2010","unstructured":"Smyth A, Oliveira GH, Lahr BD et al (2010) A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. Clin J Am Soc Nephrol 5:2060\u20132068. https:\/\/doi.org\/10.2215\/CJN.00240110","journal-title":"Clin J Am Soc Nephrol"},{"key":"7882_CR44","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1007\/s00404-025-08106-3","volume":"312","author":"C Sun","year":"2025","unstructured":"Sun C, Li X, Li X (2025) Risk factors for adverse pregnancy outcomes in systemic lupus erythematosus: a meta-analysis and systemic review. Arch Gynecol Obstet 312:1025\u20131036. https:\/\/doi.org\/10.1007\/s00404-025-08106-3","journal-title":"Arch Gynecol Obstet"},{"key":"7882_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9020166","author":"P Bradacova","year":"2021","unstructured":"Bradacova P, Slavik L, Ulehlova J et al (2021) Current promising biomarkers and methods in the diagnostics of antiphospholipid syndrome: a review. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines9020166","journal-title":"Biomedicines"},{"key":"7882_CR46","doi-asserted-by":"publisher","first-page":"1107510","DOI":"10.3389\/fimmu.2023.1107510","volume":"14","author":"S Li","year":"2023","unstructured":"Li S, Bai Y, Meng J et al (2023) Prevalence and diagnostic value of non-criteria antiphospholipid antibodies for antiphospholipid syndrome in Chinese patients. Front Immunol 14:1107510. https:\/\/doi.org\/10.3389\/fimmu.2023.1107510","journal-title":"Front Immunol"},{"key":"7882_CR47","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1093\/rheumatology\/kead303","volume":"63","author":"S Li","year":"2024","unstructured":"Li S, Zhao J, Bai Y et al (2024) Profile and clinical relevance of non-criteria antiphospholipid antibodies in patients diagnosed with or highly suspected of APS. Rheumatology (Oxford) 63:891\u2013900. https:\/\/doi.org\/10.1093\/rheumatology\/kead303","journal-title":"Rheumatology (Oxford)"},{"key":"7882_CR48","first-page":"415","volume":"139","author":"A Pajor","year":"1998","unstructured":"Pajor A, Pozsonyi T, Nekam K et al (1998) Systemic lupus erythematosus and pregnancy (effect of pre-conception hematologic disorders on fetal outcome). Orv Hetil 139:415\u2013418","journal-title":"Orv Hetil"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07882-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-025-07882-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07882-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T09:03:00Z","timestamp":1769763780000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-025-07882-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["7882"],"URL":"https:\/\/doi.org\/10.1007\/s10067-025-07882-2","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,15]]},"assertion":[{"value":"28 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was obtained from Qilu Hospital Ethics Committee (KYLL-202502\u2013048).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"In accordance with national regulations, the Ethics Committee of Qilu Hospital waived the requirement for informed consent, given the retrospective nature of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"All authors give final approval of the version that will be published.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}